Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

(NASDAQ:RVPH), Findings reinforce brilaroxazine's treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine Findings also support use of speech latency as an enrichment tool that can reduce sample-size and enhance outcomes in clinical trials for schizophrenia CUPERTINO, Calif., Jan. 08, 2026 […]

RESTEM Provides Corporate Update and Announces Strategic Priorities for 2026

MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) — RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today provided a corporate update and announced its strategic priorities for 2026. “We had a remarkable 2025, where we made significant progress across our pipeline of advanced cell therapeutics. In

GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621

(NASDAQ:GRI), New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory,

SiTime to Present at the Needham Growth Conference on January 13, 2026

(NasdaqGM:SITM), SANTA CLARA, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — SiTime Corporation (Nasdaq: SITM), the Precision Timing company, today announced that SiTime's chief executive officer, Rajesh Vashist, will participate at the 28th Annual Needham Growth Conference to be held at the Lotte New York Palace Hotel. SiTime management is scheduled to host a fireside chat

Zacatecas Silver Provides Corporate Update for 2026 and Highlights Upcoming Drill Program at Silver Project

(TSX-V:ZAC),(Pinksheets:ZCTSF),(PinkSheets:ZCTSF),(Boerse Frankfurt – Freiverkehr:7TV),(Boerse Frankfurt – Freiverkehr:7TV.F), VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — Zacatecas Silver Corp. (TSXV: ZAC | OTCQB: ZCTSF | FRA: 7TV) (“Zacatecas Silver” or the “Company”) is pleased to provide shareholders with a corporate update outlining key operational progress across its portfolio and highlighting recent regulatory developments in Mexico

California Resources Corporation and Los Angeles Rams Score in Carbon Management Initiative

(NYSE:CRC), LONG BEACH, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — California Resources Corporation (NYSE: CRC) and the Los Angeles Rams today celebrated the first year of their “Football Without the Footprint” partnership, an innovative carbon management initiative designed to reduce and offset the team's carbon emissions. The partnership demonstrates a tangible path toward decarbonization while

XWELL Reaffirms Commitment to Biosecurity, Appoints Former CDC Senior Advisor

(NASDAQ:XWEL), NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), a leading provider of wellness solutions for people on the go, today announced the continued expansion of its global biosecurity strategy, leveraging its traveler-based pathogen surveillance capabilities to support international travel hubs and large-scale mass gathering events worldwide.

The Global CEO Initiative on Alzheimer’s Disease Publishes Consensus Recommendations for Clinic-Based Digital Cognitive Assessments

PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) — The Global CEO Initiative on Alzheimer's Disease (CEOi) today announced the peer-reviewed publication of its latest manuscript by their Digital Cognitive Assessments Workgroup, “Acceptable standards for clinic-based digital cognitive assessments – recommendations from the Global CEO Initiative on Alzheimer's Disease,” in Alzheimer's & Dementia. The manuscript delivers a

Rocket Doctor AI Completes Acquisition of Alea Health to Expand Access to Therapist-Led Mental Health Care

(CNSX:AIDR),(OTC US:AIRDF),(Other OTC:AIRDF),(Boerse Frankfurt – Freiverkehr:939),(CNSX:AIDR.CN),(Boerse Frankfurt – Freiverkehr:939.F), Rocket Doctor AI has completed the acquisition of Alea Health, strengthening its AI-powered digital health platform and accelerating the delivery of physician-led care. The acquisition supports Rocket Doctor AI's mission to improve access to high-quality healthcare, particularly for underserved and remote communities across Canada and the

Collegium Provides 2026 Financial Guidance and Business Update

(NASDAQ:COLL), – Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM(R) Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million – STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) — Collegium

Scroll to Top